Bio-Gene Technology (BGT) Stock Price, News & Analysis

Company Overview

Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. Its lead products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural oil extracted from a cultivar of eucalyptus cloeziana. The company has a research collaboration agreement with James Cook University to refine the process for oil extraction; and with BASF, Grains Research and Development Corporation, and Queensland Department of Agriculture and Fisheries for testing of Flavocide in grain storage. Bio-Gene Technology Limited was incorporated in 1995 and is based in Melbourne, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: A$7.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BGT Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Bio-Gene Technology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bio-Gene Technology investors own include Revvity (PKI), Gray Media (GTN), (NESCQ) (NESCQ), Teradyne (TER), AbbVie (ABBV), Aphria (APHA) and AquaBounty Technologies (AQB).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Financial Services
• Current Symbol: ASX:BGT
• CIK: N/A
• Web: www.bio-gene.com.au
• Phone: 61 3 9628 4178
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$2.41 million
• Net Margins: -13,150.54%
• Pretax Margin: N/A
• Return on Equity: -74.33%
• Return on Assets: -44.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.49
• Quick Ratio: 6.72

Sales & Book Value

• Annual Sales: A$445.73 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 7.04
• Book Value: A$0.01 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 201,360,000
• Free Float: N/A
• Market Cap: A$7.45 million
• Optionable: Not Optionable
• Beta: 0.73